How a Korean Muscle-Saving Obesity Drug Could Change the GLP-1 Race

A Korean Bet on What GLP-1s Miss

Hanmi Pharmaceutical announced on the 24th that it has signed an exclusive global licensing deal — excluding Korea — with Genentech for its obesity drug candidate HM17321. The financial headline is easy to grasp: a $190 million upfront payment, up to $2.115 billion in milestone payments, and annual royalty obligations, bringing the total deal value to roughly $2.3 billion. In Korean won terms that figure reaches about ¥3.2 trillion. Hanmi’s stock closed at ¥540,000, up nearly 30%, and the market clearly treated this as a generational event for a company that spent years building a portfolio of specialty medicines in Korea.

The money matters. But the strategic signal matters more.

HM17321 is not another GLP-1. It is a Urocortin-2 analog — a peptide that activates the CRF2 receptor, a pathway entirely distinct from the incretin system that Novo Nordisk and Eli Lilly have built their obesity empires around. Hanmi calls it the first-in-class drug in its class to target both weight loss and muscle preservation simultaneously. If the clinical data hold up, that claim could redefine how the industry thinks about obesity treatment beyond simple calorie reduction.

The Muscle Problem Nobody Solved

Over the past three years, the GLP-1 revolution has been measured almost exclusively in kilograms shed. Semaglutide and tirzepatide deliver extraordinary results in head-to-head trials. But a growing body of evidence has surfaced showing that a significant portion of the weight lost on these drugs comes from lean tissue, not just fat. In some studies, up to 40 percent of the mass lost during the first year of treatment was muscle.

That is a serious clinical blind spot. For patients with obesity and type 2 diabetes — the very populations GLP-1s were designed to serve — losing muscle mass carries metabolic consequences that may undermine long-term outcomes. Sarcopenia, reduced bone density, and a slower resting metabolic rate all follow muscle loss. The weight may come off. But the body composition profile matters.

This is exactly the gap HM17321 aims to fill. Preclinical studies reported by Hanmi show that the drug reduces body weight while improving body composition, whether administered alone or in combination with a GLP-1 agent. The UCN2 pathway appears to shift the metabolic signature away from pure catabolism and toward a profile that spares lean mass. That mechanism has not been convincingly demonstrated by any approved obesity drug to date.

Why Genentech Is Here

Genentech’s involvement is not accidental. Roche has been cautious in the obesity space relative to Novo Nordisk and Eli Lilly, partly because its own pipeline lacks a direct GLP-1 competitor at launch scale. Licensing HM17321 gives Genentech a differentiated asset that does not cannibalize any existing product line — and one that could be positioned as an add-on therapy for patients already on GLP-1s who need better body composition outcomes.

The potential for a fixed-dose combination is a second reason this deal is strategically sharp. Hanmi explicitly notes that HM17321 is a peptide-based therapeutic developed with the possibility of co-formulation with incretin drugs in mind. If Phase 2 data support the combination hypothesis, Genentech could build a two-molecule obesity regimen around a GLP-1 backbone and a UCN2 stabilizer. That would be a completely new therapeutic architecture — not a me-too GLP-1, not a dual GIP/GLP-1 agonist, but a first-in-class combination targeting two independent metabolic pathways simultaneously.

Roche, which owns Genentech, has long sought a credible obesity entry point. This deal changes the calculus.

What the Pipeline Means

Hanmi received FDA IND approval for Phase 1 in November 2025 and is currently evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and obese patients. Phase 1 completion is the immediate milestone. From Phase 2 onward, Genentech takes over development and commercialization for the ex-Korea territory.

That handoff is significant. Phase 2 is where obesity drug programs most often fail — the doses that look promising in early safety studies frequently underperform on efficacy or reveal unexpected side-effect profiles in larger patient populations. The UCN2 pathway has not been clinically validated at scale, so the Phase 2 readout will be the first true test of whether Hanmi’s preclinical body-composition claims translate into human results.

HSR clearance under U.S. antitrust law is still pending before the deal becomes effective. That is a formality in most cases but not always a short one.

Why This Matters Beyond Seoul

For Korean biotech, this is the single largest drug-license transaction to originate from a domestically headquartered company. It repositions Hanmi from a regional specialty-pharma player to a developer with a globally competitive lead asset. More broadly, it signals that the wellspring of novel obesity mechanisms is no longer confined to the United States or Western Europe. Korea’s investment in peptide therapeutics and target-discovery platforms is producing first-in-class candidates that American big pharma is willing to pay premium prices to access.

For the global obesity market, the HM17321 deal is a reminder that the GLP-1 era is not the end of the story. Muscle preservation, body-composition optimization, and combination therapy with non-incretin pathways are the next frontier. Whoever lands a credible non-incretin obesity drug with a differentiation axis beyond “lower A1C” will have carved out a segment of the market that the current duopoly cannot easily replicate.

The Phase 2 data will determine whether HM17321 is that drug.

Until then, Hanmi’s stock price and the $2.3 billion deal are just the opening chapter.